Related Experiment Video
Updated: Aug 16, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
Pharmacological basis of akinesia in Parkinson's disease
Abstract:
Akinesia, the core symptom of the parkinsonism, which is the term having been used routinely in daily practice of neurology in describing the specific motor disturbance in parkinsonian patients, is not well defined in sense of its generating mechanism. The author tried to analyze this concept from physiological and pharmacological standpoint and classified into three subgroups, i.e. slowness of movement, poverty of movement and difficulty in initiating repetitive movement. These three groups are interpreted as due to deficiency either of DA or of NE, the former being related to the slowness of movement and the poverty of movement and the latter to the freezing symptoms in the later stage of illness. Parkinson's disease now should better be understood as the result of deficiency of several catecholamine metabolites due to chains of enzymic error, and not only of DA.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

